Vaginal Estrogen Therapy Safe for Young Endometrial Cancer Survivors, Study Finds

Despite a rising incidence of endometrial cancer in younger women, research has been limited regarding the safety of local, low-dose vaginal estrogen therapy (ET) for survivors. A new study published in Menopause, the journal of The Menopause Society, suggests this form of estrogen is not only effective in alleviating menopause symptoms but also doesn’t appear to increase the risk of cancer recurrence.

Addressing a Long-Standing Concern

Historically, all forms of hormone therapy, including low-dose vaginal estrogen, carried a “black box warning” similar to that of higher-dose, systemic therapies. This caution stemmed from concerns about potential adverse effects, despite the localized nature of vaginal ET and minimal systemic absorption. This fear may have prevented many women from utilizing a treatment with proven benefits for symptoms like vaginal dryness, painful intercourse, and urinary problems.

Endometrial Cancer Treatment and Menopause

Women undergoing treatment for endometrial cancer often experience early menopause due to hysterectomy with bilateral salpingo-oophorectomy, radiation, or chemotherapy. This early onset menopause is frequently associated with more severe hot flashes, night sweats, and genitourinary symptoms. The incidence of early-onset endometrial cancer in American women aged 50 and younger has increased from 2.2 to 3.3 per 100,000 women between 2000 and 2019, highlighting the growing need for effective and safe treatment options.

Study Findings: Minimal Risk of Recurrence

The recent study analyzed data from over 2,800 women aged 18 to 51 diagnosed with endometrial cancer, examining the employ and outcomes associated with local, low-dose vaginal ET. Researchers found that initiation of vaginal ET was relatively low (estimated at 5.6%). But, among those who did use it, short-term exposure did not elevate the risk of endometrial cancer recurrence compared to those who did not use the treatment. This is the largest U.S. Study to date assessing endometrial cancer recurrence in relation to local, low-dose vaginal ET use in survivors.

Expert Perspective

“Early detection and improved, targeted therapies have led to more women surviving their endometrial cancer diagnoses,” says Dr. Monica Christmas, associate medical director, The Menopause Society. “However, the sequalae from these life-sparing treatments often result in significant impairment to quality of life and sexual function. Genitourinary symptoms associated with menopause rarely improve without treatment and are exacerbated in the context of abrupt, early menopause. Helping survivors of endometrial cancer to make evidence-based decisions about their care is empowering, especially during a vulnerable time. Expanding treatment options to include local, low-dose vaginal estrogen therapy in this population will have long-lasting benefits.”

Looking Ahead

These findings offer reassurance to both patients and healthcare providers, potentially leading to more informed decisions regarding the management of menopause symptoms in young endometrial cancer survivors. Further research will continue to refine our understanding of the long-term benefits and risks of vaginal estrogen therapy in this population.

Source: Vaginal Estrogen Therapy Not Linked to Cancer Recurrence in Survivors of Endometrial Cancer, Menopause, March 4, 2026.